These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 27082537)

  • 1. Could Pharmacologic Lung Deflation Modify Cardiac Structural and Functional Alterations?
    Savas G; Kalay N; Gulmez I
    Am J Respir Crit Care Med; 2016 Apr; 193(8):932. PubMed ID: 27082537
    [No Abstract]   [Full Text] [Related]  

  • 2. Chronic Obstructive Pulmonary Disease: When Pulmonologists Do Something Good for the Heart.
    Watz H
    Am J Respir Crit Care Med; 2016 Apr; 193(7):703-4. PubMed ID: 27035775
    [No Abstract]   [Full Text] [Related]  

  • 3. Lung Deflation and Cardiovascular Structure and Function in Chronic Obstructive Pulmonary Disease. A Randomized Controlled Trial.
    Stone IS; Barnes NC; James WY; Midwinter D; Boubertakh R; Follows R; John L; Petersen SE
    Am J Respir Crit Care Med; 2016 Apr; 193(7):717-26. PubMed ID: 26550687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trelegy Ellipta--a three-drug inhaler for COPD.
    Med Lett Drugs Ther; 2018 May; 60(1547):86-88. PubMed ID: 29913467
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
    Boscia JA; Pudi KK; Zvarich MT; Sanford L; Siederer SK; Crim C
    Clin Ther; 2012 Aug; 34(8):1655-66.e5. PubMed ID: 22789766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ▼Relvar Ellipta for COPD.
    Drug Ther Bull; 2014 Jun; 52(6):66-9. PubMed ID: 24904005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spotlight on fluticasone furoate/umeclidinium/vilanterol in COPD: design, development, and potential place in therapy.
    Lal C; Strange C
    Int J Chron Obstruct Pulmon Dis; 2017; 12():135-140. PubMed ID: 28115838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluticasone furoate and vilanterol inhalation powder for the treatment of chronic obstructive pulmonary disease.
    Matera MG; Capuano A; Cazzola M
    Expert Rev Respir Med; 2015 Feb; 9(1):5-12. PubMed ID: 25482512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relvar Ellipta for asthma.
    Drug Ther Bull; 2014 Aug; 52(8):93-6. PubMed ID: 25125553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Importance of inhaled corticosteroids under discussion].
    Jäger-Becker D
    MMW Fortschr Med; 2016 Jun; 158(11):75. PubMed ID: 27271423
    [No Abstract]   [Full Text] [Related]  

  • 11. Breo Ellipta: An Inhaled Fluticasone/ Vilanterol Combination for COPD.
    Med Lett Drugs Ther; 2013 Sep; 55(1424):69-71, 45-8. PubMed ID: 26839934
    [No Abstract]   [Full Text] [Related]  

  • 12. [Once daily with a powder inhaler].
    Fath R
    MMW Fortschr Med; 2015 Jun; 157(11):66. PubMed ID: 26049359
    [No Abstract]   [Full Text] [Related]  

  • 13. A phase III randomised controlled trial of single-dose triple therapy in COPD: the IMPACT protocol.
    Pascoe SJ; Lipson DA; Locantore N; Barnacle H; Brealey N; Mohindra R; Dransfield MT; Pavord I; Barnes N
    Eur Respir J; 2016 Aug; 48(2):320-30. PubMed ID: 27418551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of once-daily fluticasone furoate/vilanterol (100/25 mcg) versus twice-daily fluticasone propionate/salmeterol (250/50 mcg) in COPD patients.
    Dransfield MT; Feldman G; Korenblat P; LaForce CF; Locantore N; Pistolesi M; Watkins ML; Crim C; Martinez FJ
    Respir Med; 2014 Aug; 108(8):1171-9. PubMed ID: 24998880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluticasone furoate/vilanterol (100/25; 200/25 μg) improves lung function in COPD: a randomised trial.
    Martinez FJ; Boscia J; Feldman G; Scott-Wilson C; Kilbride S; Fabbri L; Crim C; Calverley PM
    Respir Med; 2013 Apr; 107(4):550-9. PubMed ID: 23332861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhaled corticosteroids in severe COPD.
    Bousquet J
    Lancet Respir Med; 2013 May; 1(3):177-8. PubMed ID: 24429112
    [No Abstract]   [Full Text] [Related]  

  • 17. A randomised, phase III trial of once-daily fluticasone furoate/vilanterol 100/25 μg versus once-daily vilanterol 25 μg to evaluate the contribution on lung function of fluticasone furoate in the combination in patients with COPD.
    Siler TM; Nagai A; Scott-Wilson CA; Midwinter DA; Crim C
    Respir Med; 2017 Feb; 123():8-17. PubMed ID: 28137501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between exercise endurance and static hyperinflation in a post hoc analysis of two clinical trials in patients with COPD.
    Singh S; Maltais F; Tombs L; Fahy WA; Vahdati-Bolouri M; Locantore N; Riley JH
    Int J Chron Obstruct Pulmon Dis; 2018; 13():203-215. PubMed ID: 29386889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of pneumonia on routine chest radiographs in patients with COPD: a post hoc analysis of two 1-year randomized controlled trials.
    Rubin DB; Ahmad HA; O'Neal M; Bennett S; Lettis S; Galkin DV; Crim C
    Int J Chron Obstruct Pulmon Dis; 2018; 13():189-201. PubMed ID: 29386888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic safety of fluticasone furoate/vilanterol combination.
    Lipworth B
    Thorax; 2013 Dec; 68(12):1165. PubMed ID: 23821392
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.